Epoprostenol intravenous - Actelion

Drug Profile

Epoprostenol intravenous - Actelion

Alternative Names: ACT-385781A; Caripul; EPO-ES; Epoprostenol ACT; Epoprostenol sodium thermostable - Actelion; Valetri; Veletri

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator GeneraMedix
  • Developer Actelion Pharmaceuticals
  • Class 2 ring heterocyclic compounds; Antihypertensives; Prostaglandins; Small molecules; Vasodilators
  • Mechanism of Action Epoprostenol receptor agonists; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Pulmonary arterial hypertension

Most Recent Events

  • 02 Mar 2017 Registered for Pulmonary arterial hypertension (In adolescents, In children, In infants, In neonates) in Japan (IV)
  • 21 Jul 2016 Launched for Pulmonary arterial hypertension in Greece (IV) befroe July 2016
  • 01 Jun 2015 Launched for Pulmonary arterial hypertension in France (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top